Mike Ellis, Ph.D., joined BeiGene in 2020 as Vice President, Alliance Management. He was previously VP of Business Operations at Pionyr Immunotherapeutics, where he provided leadership to partnering, strategic portfolio planning, and corporate strategy initiatives. Prior to that, Mike spent five years as Senior Director of Alliance Management at Regeneron Pharmaceuticals. Over the course of his career, Mike has built a proven track record of driving corporate growth in highly innovative, entrepreneurial companies.

Lucy Li, Ph.D., is Executive Director of Corporate Strategy and oversees the development of the company strategy and growth plan. Dr. Li joined BeiGene in 2015 and has served various leadership roles in strategy and investor relations including leading the development of BeiGene’s next 10-year corporate strategy. Prior to joining BeiGene, Dr. Li was a strategic consultant with Navigant Consulting (now a Guidehouse company) and Campbell Alliance Consulting (now Syneos Health Consulting). During the strategy consulting career, Dr. Li established a diverse set of experience across therapeutic areas and functional areas including corporate and portfolio strategy, marketing, market access, and finance. Dr. Li received a bachelor’s degree from Peking University and a Ph.D. in Neuroscience and Neurology from Washington University in St. Louis.

Yan Blake Liu, MD, MBA, joined BeiGene in March 2021 as Executive Director at the newly formed Clinical Business Development Insights (CBDi), reporting to Angus Grant. Dr. Liu, a trained Cardiologist from Beijing, brought nearly 20 years of experience in the U.S. biotech/pharmaceutical industry to BeiGene. His recent roles prior to joining BeiGene include CI Lead for Heme (including CAR-T) and IO at Novartis, CI Lead for Opdivo in Melanoma, RCC and Lung at BMS, and Marketing Director, Cardiometabolic at Quest Diagnostics. Dr. Liu leads the CBDi function to support Clinical Development to build up BeiGene’s pipeline, enhance BD opportunity search capabilities from external innovations, and assist in the development of corporate strategy. Additionally, the CBDi team will take the lead in conference coverage, emerging technology/MoA assessment, and competitive and indication landscape evaluation with cross-functional teams at BeiGene. Dr. Liu holds an MD from China Medical School and an MBA from the University of Maryland, College Park, MD.

Lusong Luo, Ph.D., is SVP & Head of External Innovation and one of the founding scientists at BeiGene. Prior, Dr. Luo was SVP & Head of Discovery Biology at BeiGene. In addition to his current role at BeiGene, Dr. Luo serves as the acting CEO and President of MapKure, LLC, as well as Board member for MapKure and Boston Immune Technologies & Therapeutics. Before joining BeiGene, Dr. Luo held positions at BioDuro as Sr. Director and Director of Discovery Biology. He has also spent a number of years at GlaxoSmithkline Oncology CEDD, where he served as Group Manager, Research Investigator, and Principal Scientist. Dr. Luo was a key member of a number of oncology drug discovery/development teams that have contributed to the discovery and development of over a dozen clinical compounds, among which five have obtained regulatory approvals. Dr. Luo has published more than 60 research papers, reviews, and book chapters. He was trained with Professor. Christopher T Walsh at Harvard Medical School and obtained his Ph.D. in Biochemistry from the University of New Mexico.

Dewan Zeng Ph.D., MBA, joined BeiGene in 2017 as Senior Director, Clinical Sciences and transitioned to BD in Jan 2019.  In her current role as Head of Search and Evaluation, she leads a team of professionals to identify and evaluate innovative products and technologies to complement BeiGene’s portfolio. Her team is also responsible for due diligence on in-licensing, out-licensing and clinical collaboration deals globally. Prior to joining BeiGene, Dewan worked at Pfizer, Gilead and CV Therapeutics and held various leadership roles in clinical development and translational research. In her 23 years of pharmaceutical career, she led multiple global development programs from IND to completion of Ph1/Ph2/Ph3 clinical studies and supported NDA submissions and approvals of three pharmaceutical products in U.S., Europe and China. Dewan received her BS in Biochemistry from Peking University, PhD in Biochemistry from University of Virginia, and MBA in Global Business Strategy from Cal State University East Bay. She completed her post-doctoral training at UCSF.

Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant oversees strategy, business development and alliance management, and helps drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.

Clare Fisher joined BeiGene in July 2021 as SVP Business Development and Mergers & Acquisitions, bringing over 20 years of experience in healthcare, including leadership roles in corporate and business development, M&A, and strategy. Prior to joining Beigene, Ms. Fisher served as Kaleido Bioscience’s Chief Business Officer, a company dedicated to targeting the microbiome to treat a variety of diseases. Ms. Fisher previously also held senior global roles at Shire plc, Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation leading collaborations, licensing, M&A, investments and divestments across many technologies and therapeutic areas. Ms. Fisher holds a B.S. in Biochemistry from the University of Bath, as well as an M.B.A. from Henley Management College in the U.K.

Guillaume Vignon, Ph.D., joined BeiGene in 2018 as our Senior Vice President, Business Development. Dr. Vignon formerly held the position of Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA/EMD Serono. In this position, Dr. Vignon led a team of business development professionals responsible for structuring and negotiating terms of licensing agreements for oncology and immuno-oncology assets from discovery to commercial stage. As part of his mandate, he provided business development expertise and strategic input into the Oncology strategy. Throughout his career at Merck KGaA, Dr. Vignon forged and successfully established several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery with academia, biotech, and pharma. Dr. Vignon holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Institut Pasteur, Paris, France and an MBA from Hult International Business School, Cambridge, MA.